Key Takeaways
- A first launch requires the company itself to become commercially capable—not only promotional readiness.
- If departments describe the patient journey differently, commercial alignment is incomplete.
- Coverage should not be confused with access; organization and governance determine whether plans can execute.
- Readiness is about identifying the greatest risks while leadership still has time to act.
A first product launch represents a fundamental transformation for an emerging biotechnology company.
Success requires far more than preparing promotional materials and recruiting a sales team. The company itself must become commercially capable.
Leadership should evaluate readiness across eight areas. For a structured engagement, see PharmaKonsult’s biotech launch readiness assessment.
Executive opinion paper
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
